IOVA Similar Chart Price Prediction
The price of IOVA is predicted to go up 7.92%, based on the high correlation periods with PFX. The similarity of these two price pattern on the periods is 97.47%.
IOVA
PFX
Up: 7.92%Similarity: 97.47%
IOVA Revenue Forecast
IOVA EPS Forecast
IOVA FAQs
What is bull’s view on IOVA?
What is bear's view on IOVA?
What is IOVA revenue forecast for next quarter？
What is IOVA eps forecast for next quarter？
IOVA Analyst's Forecast
Joseph Catanzaro
Piper Sandler
Hold
2025-01-31
Price Target
$10 → $7.5
Upside
+28.21%
Piper Sandler analyst Joseph Catanzaro lowered the firm's price target on Iovance Biotherapeutics to $7.50 from $10 and keeps a Neutral rating on the shares. Ahead of FY24 earnings, the firm reconnected with 6 ATCs to discuss expectations for Amtagvi in 2025. All ATCs characterized their current infusion volumes as at steady state, and most brought up emerging competitive dynamics in post-PD-1 melanoma. Taken together, this feedback suggests that the doubling of monthly infusions is required to achieve 2025 guidance/consensus could prove challenging, Piper says. As such, the firm takes down its FY25 total revenue estimate to $403M from $450M, below both current consensus and company guidance.
David Dai
UBS
Strong Buy
2024-10-24
Price Target
$17
Upside
+60.98%
